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Eﬃcacy of desloratadine in intermittent allergic rhinitis:
a GA2LEN study
Background: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines
proposed a classiﬁcation for allergic rhinitis based on the duration of symptoms
(intermittent, persistent) rather than on the time of allergen exposure (seasonal,
perennial). There is no placebo-controlled, randomized clinical trial on inter-
mittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for
the ﬁrst-line treatment of seasonal and perennial allergic rhinitis.
Objectives: To assess the eﬃcacy and safety of DL in subjects with IAR based on
the ARIA classiﬁcation.
Methods: Patients over 12 years of age with IAR were assessed over 15 days of
treatment with DL 5 mg once daily (n = 276) or placebo (n = 271). The
primary endpoint was the AM/PM reﬂective total 5 symptom score (T5SS).
Secondary endpoints included AM/PM instantaneous T5SS and individual
symptoms, therapeutic response, symptom severity by visual analogue scale, and
quality-of-life.
Results: The mean reduction of AM/PM reﬂective T5SS was signiﬁcantly greater
with DL than with placebo over 15 days ()3.01 vs )2.13, P < 0.001) and on
each individual day (P < 0.05). Mean AM instantaneous T5SS was reduced
signiﬁcantly with DL compared to placebo as early as day 2 ()1.84 vs )0.89;
P < 0.001). The therapeutic response and improvement in quality-of-life were
signiﬁcantly greater with DL than with placebo (P < 0.001 for each). The
frequency of treatment-related adverse events was low and similar between DL
(7.2%) and placebo (7.0%).
Conclusions: This is the ﬁrst large trial to show that treatment can be eﬀective in
IAR. Desloratadine was eﬀective and safe.
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In 2001, allergic rhinitis was classiﬁed by the Allergic
Rhinitis and its Impact on Asthma (ARIA) guidelines into
four categories (1): mild and moderate/severe intermittent;
and mild and moderate/severe persistent depending on the
severity of symptoms, quality-of-life, and the duration of
symptoms. The terms IAR or PER are not interchangeable
with the terms seasonal or perennial allergic rhinitis. The
recent ARIA update has conﬁrmed that this classiﬁcation
is useful because it more closely reﬂects patients needs and
real life than the previous classiﬁcation (2, 3).
In the ARIA documents, a stepwise pharmacologic
treatment is proposed based on the ARIA categories.
There is no correlation between the ARIA categories and
the previous classiﬁcation of rhinitis (4, 5), and in its last
edition, the ARIA panel members proposed not to
extrapolate the results for treatment of intermittent allergic
rhinitis (IAR) and persistent allergic rhinitis (PER) from
randomized clinical trials (RCTs) carried out with the old
classiﬁcation (3). Two RCTs with oral H1-antihistamines
have been carried out in PER (6, 7), but there is no RCT in
IAR although one was incorrectly claimed to study IAR
(8). A large RCT in intermittent rhinitis will have an
impact on the revision of the ARIA guidelines.
The assessment of RCT eﬃcacy in allergic rhinitis is
usually based on symptoms, but it is now recognized that
allergic rhinitis comprises more than the classical symp-
toms of sneezing, rhinorrhea and nasal obstruction. It is
also associated with signiﬁcant impairments in social life
(9–11) andwork (12, 13). In someRCTs, quality-of-life has
been used as a primary end point (6, 14). Moreover, visual
analogue scales (VAS) are quantitative measures which
have been used in RCTs in rhinitis (14–17) but there are no
longitudinal studies onVASmeasured each day of the trial.
Desloratadine (DL) is eﬀective and safe in the treat-
ment of allergic rhinitis. It was shown to improve
symptoms and quality-of-life in seasonal (8, 18–23) and
perennial allergic rhinitis (24, 25). However, it has not yet
been tested in ARIA-deﬁned IAR or PER.
The aim of the Aerius Control: Clinical and Evaluative
Proﬁle of Treatment (ACCEPT-1) study was to evaluate
the eﬃcacy and safety of DL in subjects with IAR as
deﬁned by the ARIA guidelines, to study the onset of
eﬃcacy and its duration over a 2-week treatment period.
The ACCEPT study also provided an opportunity to
collaborate with GA2LEN (26, 27), a consortium of
leading European research centers specializing in allergic
diseases, to characterize the patterns of sensitization to
seasonal and perennial allergens at each study site.
Methods
Participants
Subjects were included in the study after written informed consent
was obtained. The study conformed to Good Clinical Practices and
was approved by local ethics committees. All subjects fulﬁlled the
following inclusion criteria: patients 12 years of age or older, of either
sex, with at least a 2-year history consistent with symptoms of allergic
rhinitis deﬁned according to the International Consensus on Rhinitis
(28) and meeting the criteria for IAR according to the ARIA classi-
ﬁcation (1) (symptoms of allergic rhinitis present <4 days/week or
for <4 consecutive weeks/year). Patients had to have moderate/se-
vere symptoms. On the day of inclusion, at the start of the Run-in
Period, the reﬂective total 5 symptom score (T5SS) was at least 6. For
a subject to be randomized, the sum of the daily averages of the diary
recordings of the 12-h AM plus PM reﬂective T5SS collected during
4 days and the AM reﬂective T5SS on the morning of the randomi-
zation had to be ‡ 30. Allergy was deﬁned by positive skin prick tests
to common aeroallergens carried out according to the GA2LEN skin
test study (29). None of the patients had taken any medication for
allergic rhinitis during the 14 days prior to randomization. Mainte-
nance regimens of immunotherapy were permitted.
Interventions
DL 5 mg or placebo were administered orally in identical tablets
each morning within 1 h after awakening. The study consisted of two
periods: TheRun-in Period lasted 4–14 days. If subjects had suﬃcient
symptoms (‡ 30) for 4 days, they were randomized to DL 5 mg OD
or placebo for 14 days. Visits occurred at day 1 (baseline visit) and 15
(Final visit). No rescue medication was allowed during the trial.
Objectives
The aim of the present study was to assess the eﬃcacy and safety
of DL in patients suﬀering from IAR as deﬁned by ARIA. This
multicenter, multinational, randomized, double-blind, placebo-
controlled, parallel-group Phase IV study of DL 5 mg (OD in the
morning) was conducted at 60 sites in 15 countries (Belgium, Canada,
Denmark, Finland, France, Germany, Greece, Hungary, Italy, The
Netherlands, Portugal, Russia, Spain, Sweden, and Turkey) from
September 5, 2006 to November 21, 2007. The primary outcome
measure was the per-protocol reﬂective T5SS in the intent-to-treat
population. RQLQ (10) was a key secondary outcome measure.
Instantaneous T5SS, individual symptom scores, VAS levels (30, 31),
subjects assessment of response were secondary endpoints, and
WPAI-AS (12, 13) were used as exploratory outcome measures.
Outcomes
Symptoms severity rating scale assessment. Severity scores for ﬁve
(T5SS) individual allergic rhinitis signs/symptoms (nasal congestion/
stuﬃness, sneezing, rhinorrhea/nasal discharge, nasal pruritus, and
eye itching) were recorded in subject daily diaries in the morning and
evening. Each sign/symptom was scored 0–3 (none = 0–3 = severe)
twice daily, in themorning (AM)within 1 hof awakening andprior to
dosing (reﬂective) and in the evening (PM), 12 h later. In both the
AM and PM, symptom severity was assessed over the previous 12 h
(reﬂective) and at the time of the assessment (instantaneous). The
T5SS is the sum of the ratings for the individual scores.
Symptom severity visual analogue scale (VAS) assessment. The 24-h
reﬂective VAS rating was recorded in subject daily diaries each
morning within 1 h of awakening and prior to dosing (AM) at the
baseline Visit and for each treatment day. Scores range from not at
all bothersome (0 mm) to very bothersome (100 mm) (30, 31).
Subjects evaluation of therapeutic response to treatment. The
subjects response to treatment was assessed by the subject alone
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at the Final Visit (day 15). Evaluation included the entire time
period since the start of treatment (baseline) up to and including the
Final Visit compared to baseline. The assessment was scored as
follows in a 5-point scale: Complete Relief, Marked Relief,
Moderate Relief, Slight Relief, or No Relief.
The Rhinoconjunctivitis Quality-of-Life Questionnaire-Stan-
dardized Version (RQLQ-S) (10), 28 questions, was completed by
the subject at the baseline and Final Visits only in countries where
the questionnaire has been translated into the native language and
in subjects ‡18 years of age.
Interference with sleep and daily activities. At the Run-in Visit,
during the Run-in Period (days –4 to –1), and continuing through
the Final Visit (day 15), subjects recorded in their daily diaries (at
the same times as recording the T5SS ratings) the two interference
rating scores, namely:
• once daily (AM) evaluations of interference with sleep caused
by allergic rhinitis symptoms during the previous night and;
• once daily (PM) evaluations of interference with daily activities
caused by allergic rhinitis symptoms during that day (except
day 15).
Work productivity questionnaire. At the baseline Visit and through
the Final Visit, the allergic rhinitis speciﬁc Work Productivity and
Activity Impairment questionnaire (WPAI-AS) was completed by
the subjects (12, 13) (online repository).
Study drug compliance with study drug was assessed by com-
paring the number of tablets dispensed at the baseline Visit with
the number returned at the ﬁnal Visit. Subjects were considered
non-compliant if they had taken <80% or more than 120% of
drugs.
Adverse events. Adverse events were recorded at each visit on the
case report form (CRF) and were coded using the Medical
Dictionary for Regulatory Activities (MedDRA) (32).
Sample size. A sample size of approximately 540 subjects (270 on
DL 5 mg, 270 on placebo) was calculated to provide at least 90%
power to detect a 1.0 point treatment diﬀerence in change from
baseline reﬂective T5SS averaged over days 1–15, with a 5% two-
sided level of signiﬁcance and an assumed standard deviation of 3.5.
A 1.0 treatment diﬀerence is a 12.5% improvement over placebo,
assuming a baseline score of 8.0 points.
Randomization. Subjects were randomized in a 1:1 ratio to the two
treatment arms by means of a computer-generated randomization
schedule.
Statistical analysis. The two-way analysis of variance (anova)
model with treatment and side eﬀects was used to examine
treatment diﬀerences of T5SS, RQLQ, individual diary symptoms,
interference with sleep and daily activities, the VAS assessment and
WPAI-AS. The Mantel–Haenzel test was used for the subjects
evaluation of therapeutic response.
Multiplicity. The study has one primary endpoint and one key
secondary endpoint for one treatment comparison (DL vs placebo).
The key secondary endpoint was tested only if the primary endpoint
was statistically signiﬁcant. Therefore the overall a of 5% is
preserved. The results of the additional secondary and exploratory
endpoints were examined only to conﬁrm the results of the primary
analysis. Thus no multiplicity adjustments to the overall a were
applied to the additional secondary endpoints.
Missing data. All randomized subjects were included in the analysis
(intent-to-treat principle). However, subjects with a missing evalu-
ation at a given visit or time point, including subjects without a
baseline score for a given change-from-baseline evaluation, were
excluded from the analysis for that evaluation. This exclusion was
applied to analyses at each visit and diary interval. If any of the
individual symptom scores were missing for a subject, the corre-
sponding T5SS was also considered missing on a given day. For the
analyses where AM or PM diary data were to be averaged for each
day, if an AM or PM diary reading was missing on any given day,
the average for that day was equal to the non-missing value.
Interval averages were the mean of all non-missing values within
that interval (e.g. baseline and days 1–15).
For diary evaluations, several impact analyses were performed to
assess the inﬂuence of early discontinuations such as looking at
complete subjects only, last observation carried forward (LOCF)
and substitution of worst-case values.
Results
Participant flow and number analyzed
Six hundred and sixty-six subjects were screened and 547
subjects were randomized and valid for inclusion in the
safety protocol. A total of 262 subjects treated by DL and
256 subjects treated by placebo completed the study. The
disposition of study subjects is shown in Fig. 1.
Baseline data
The baseline demographic data at run-in were similar in
both groups (Table 1).
Patient compliance
Only four subjects in the DL group and three in the
placebo group were not compliant and were therefore
excluded from the analysis.
Outcomes and estimation
An assumed diﬀerence of 1.0 unit between treatments for
the primary eﬃcacy variable was used to calculate the
sample size. The observed diﬀerence was 0.9 with a
standard deviation smaller than assumed.
Table 2 represents the intent-to-treat analysis. There
was a 37.7% change in the primary end point (T5SS
reﬂective) in the DL group and a 27.8% change in the
placebo group (P < 0.001). The secondary outcome
(RQLQ) was signiﬁcantly improved in the DL group by
comparison to the placebo group. All RQLQ dimensions
but sleep were signiﬁcantly improved in the DL group by
comparison to placebo. All secondary and exploratory
outcomes were also signiﬁcantly improved by DL. The
eﬃcacy of DL was found for both instantaneous and
reﬂective symptoms.
When individual symptoms were assessed, all nasal
symptoms including nasal congestion were signiﬁcantly
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improved in the DL group by comparison with placebo,
but to a lesser extent for the single ocular symptom
measured (reﬂective eye itching, P < 0.047, and instan-
taneous eye itching, P < 0.023).
The eﬃcacy of DL was signiﬁcant at day 1 and
continued throughout the study. However, the maximum
eﬀect was observed after one week of treatment for the
primary outcome measure (Fig. 2A). For VAS, a signi-
ﬁcant diﬀerence was also demonstrated at day 1 and
continued throughout the study (Fig. 2B). The changes in
PAI-AS are presented in Fig. S1.
Adverse events
Table 3 presents the adverse events occurring in more
than 1% of subjects in any group. Both treatments
were well tolerated and the rate of severe adverse
events was identical and very low in both groups. No
life-threatening adverse event occurred. Four adverse
events in each group led to the discontinuation of the
treatment. There were no abnormal laboratory and
vital signs listed.
Discussion
In the present study, we found that DL is a safe and
eﬀective treatment of IAR as deﬁned by ARIA (1). This is
the ﬁrst study to use the ARIA criteria on IAR. Because
the methods used are recommended for the study of
medications in allergic rhinitis and the sample size is
suﬃcient, this study will help to support future ARIA
guidelines.
Validated methods were used to enroll patients and
study the eﬃcacy of DL. The primary outcome measure
was the recommended total score of ﬁve symptoms. This
score includes nasal congestion which is improved by
DL (8). Other accepted outcomes were used including
RQLQ and WPAI-AS. Assessment of symptom severity
by VAS was also used as a secondary outcome measure.
Interestingly, all the primary, secondary and exploratory
outcomes showed a signiﬁcant diﬀerence when com-
pared with placebo.
The patients were well characterized according to
ARIA, and, for the ﬁrst time, IAR has been studied.
Other studies were claimed to have been carried out in
IAR (8, 33), but the selection of the subjects was not in
accordance with ARIA. Very few drop outs were
observed in the study and the compliance to the treatment
was excellent. The number of centers was very high and
this could have induced an heterogeneity of the study
possibly related to a smaller diﬀerence between placebo
and DL. The signiﬁcance of the results despite this
heterogeneity is in favor of the importance of the results.
Desloratadine was eﬀective over a 24 h period as
already shown. Improvements in daily diary symptom
547 subjects included
276 subjects
Desloratadine 5 mg OD
7 subjects
Withdrawal
- 4 adverse event
- 2 treatment failure
- 1 personal reason
11 subjects
Withdrawal
- 4 adverse events
- 3 treatment failure
- 4 personal reasons
4 subjects
Noncompliance
3 subjects
Lost to follow-up
262 subjects 256 subjects
1 subject
ineligible
3 subjects
Noncompliance
271 subjects
Placebo
Figure 1. Disposition of subjects.
Table 1. Demographic data
DL 5 mg Placebo P-value
N 276 271
Sex (% males) 44 39 NS
Age (years, mean € SD) 33.8 € 12.0 34.6 € 12.8 NS
Asthma (%) 16.7 17.0 NS
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ratings were corroborated by VAS data, which improved
by 31% with DL and by 17% in the placebo group from
day 1 to 15. Symptoms were signiﬁcantly improved by
DL on day 1 and over the course of the 15-day study.
Although greater reductions from baseline in subjects
treated with DL were observed from Week 1 to 2 for all
ﬁve symptoms, it is possible that the intermittent nature
of IAR resulted in some attenuation of treatment
diﬀerences between the two groups over time. The
impact of DL on ocular pruritus was the least robust
among all of the symptoms. The placebo scores contin-
ued to fall because of the nature of the disease
(intermittent) and it was very important to conﬁrm that
after 2 weeks, the treatment eﬀect was still signiﬁcant.
This has an important clinical implication. On the other
hand, interestingly, VAS levels were falling less than
total symptom scores.
The symptoms of AR can cause considerable morbidity
in physical and emotional comfort and functional capa-
city. Subjects rated symptom severity over the previous
24 h using a 100-mm VAS. The mean baseline VAS
ratings were 57.4 in the DL group and 56.7 in the placebo
group. These results show that most patients were in the
moderate-severe category (30). At the end of the study,
subjects in the DL group showed a signiﬁcantly greater
improvement in VAS rating compared with placebo. In
ACCEPT-1, the mean total RQLQ-S score at baseline
was 2.96 in the DL group and 2.80 in the placebo group
(maximum score 6.0). These results conﬁrm the VAS
rating and underline that patients presented moderate-
severe IAR (13). By study end, the total RQLQ global
score was signiﬁcantly improved.
Disordered sleep associated with allergic rhinitis, a
bothersome issue on its own, also induces secondary
ramiﬁcations on productivity, including next-day fatigue,
school absence, and poor task performance (34). In the
current study, improvements in sleep scores were signif-
icantly greater with DL when compared with placebo,
and possibly related to improvements in nasal congestion
scores.
The ACCEPT-1 study is also the ﬁrst study to
demonstrate that symptom improvement with DL
treatment has an economically relevant impact on the
productivity of subjects with IAR. Improvement in
work/school productivity and daily activity as measured
by the WPAI-AS was signiﬁcantly greater with DL
than with placebo. Other studies have found an eﬀect
on work productivity (35) but there was no objective
assessment. Desloratadine treatment signiﬁcantly re-
duced the work absenteeism and presenteeism associ-
ated with symptoms of AR. In the United States, AR
has been estimated to be responsible for 2 million
school days missed and 3.5 million workdays lost
annually (36). In a survey of American employees,
AR symptoms were responsible for an average of
3.6 missed workdays/year and contributed to decreased
productivity for 2.3 h/workday when symptoms were
present (37).
The rate of treatment-related AEs was similar between
DL and placebo, conﬁrming the results of previous studies
that have found DL safe and eﬀective (22, 25). Addition-
ally, numerous studies have found DL to be relatively free
of sedative side eﬀects or eﬀects on performance, even at
excessive doses, most likely due to its apparent lack of
Table 2. Primary, secondary and exploratory outcome variables (intent-to-treat analysis)
DL 5 mg Placebo
P -value
Baseline LS
mean € SEM
Days 1–15 LS
mean € SEM
Baseline LS
mean € SEM
Days 1–15 LS
mean € SEM
AM/PM T5SS reflective 8.71 € 0.15 )3.19 € 0.22 8.49 € 0.15 )2.29 € 0.22 <0.001
RQLQ total score (at endpoint) 2.96 € 0.08 )1.10 € 0.10 2.80 € 0.08 )0.73 € 0.10 <0.001
AM/PM T5SS instantaneous 8.30 € 0.17 )2.86 € 0.20 8.17 € 0.17 )1.90 € 0.20 <0.001
AM/PM rhinorrhea reflective 1.81 € 0.04 )0.58 € 0.05 1.75 € 0.04 )0.38 € 0.05 <0.001
AM/PM Nasal congestion reflective 1.96 € 0.04 )0.56 € 0.05 1.87 € 0.04 )0.43 € 0.05 0.013
AM/PM sneezing reflective 1.65 € 0.04 )0.64 € 0.05 1.61 € 0.04 )0.42 € 0.05 <0.011
AM/PM Nasal itching reflective 1.71 € 0.04 )0.67 € 0.05 1.65 € 0.04 )0.43 € 0.05 <0.001
AM/PM Eye itching reflective 1.38 € 0.06 )0.58 € 0.05 1.45 € 0.06 )0.46 € 0.05 0.047
AM/PM rhinorrhea instantaneous 1.76 € 0.05 )0.54 € 0.05 1.72 € 0.05 )0.33 € 0.05 <0.001
AM/PM Nasal congestion instantaneous 1.94 € 0.05 )0.52 € 0.05 1.87 € 0.05 )0.39 € 0.05 0.009
AM/PM sneezing instantaneous 1.56 € 0.05 )0.59 € 0.05 1.51 € 0.05 )0.36 € 0.05 <0.001
AM/PM Nasal itching instantaneous 1.65 € 0.05 )0.63 € 0.05 1.61 € 0.05 )0.37 € 0.05 <0.001
AM/PM eye itching instantaneous 1.38 € 0.06 )0.58 € 0.05 1.46 € 0.06 )0.45 € 0.05 0.023
Sleep interference 1.37 € 0.06 )0.39 € 0.05 1.38 € 0.06 )0.27 € 0.05 0.039
Activity interference 1.72 € 0.05 )0.60 € 0.06 1.66 € 0.05 )0.40 € 0.06 <0.001
Symptom severity reflective (VAS) 57.4 € 1.36 )17.2 € 1.50 56.76 € 1.35 )10.9 € 1.49 <0.001
Subjects evaluation of response NA 3.24 € 0.10 NA 3.66 € 0.10 <0.001
WPAI-AS Overall work impairment 46.38 € 2.35 )15.0 € 2.78 41.37 € 2.27 )5.7 € 2.69 0.002
Activity impairment 48.24 € 1.85 )15.3 € 2.20 46.04 € 1.87 )9.2 € 2.22 0.007
LS Means, SEM (standard error of the LS means) are obtained from an ANOVA model with treatment and site effects; NA, not applicable.
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penetration of the blood–brain barrier. The results of this
study also corroborate these data, with a low incidence of
somnolence, similar to that seen with placebo.
Around 30% of patients consulting in primary care and
20% in specialist care (in Europe) present intermittent
rhinitis. The present study is important for the following
points: (1) Intermittent rhinitis is not identical to
seasonal, thus there was a need to determine whether an
oral H1-antihistamine was eﬀective in this situation. (2)
Although likely, this had to be conﬁrmed. (3) The eﬃcacy
of the treatment was signiﬁcant after 1 day. This was also
likely but had to be conﬁrmed. It was totally unknown
whether the eﬃcacy of the treatment could be maintained
over a 2-week period due to the nature of the disease
(intermittent). This is a major ﬁnding of the study.
Importantly, this is the ﬁrst GA2LEN clinical trial.
This European network of excellence (26, 27) can
therefore be used to perform and enroll well-characte-
rized patients for a large RCT.
Conclusions
This is the ﬁrst study to demonstrate that a daily
antihistamine (desloratadine) can reduce the total
symptom burden and individual symptom scores associ-
ated with IAR, with a safety proﬁle similar to that of
placebo. Improvements were also noted in various
measures of QoL and school/work productivity, issues
that are of great importance to those patients with allergic
rhinitis. This study will have an impact on the ARIA
guidelines already translated into 52 languages.
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Figure 2. Evolution of reﬂective T5SS (A) and symptom
severiry by VAS (B). LS means obtained from an anova model
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Table 3. Incidence of treatment-related adverse events reported by ‡1% of
subjects in either treatment group
DL 5 mg
(N = 271)
Placebo
(N = 276)
Report of adverse any event 20 (7.2%) 19 (7.0%)
Adverse event leading to treatment discontinuation 4 (1.4%) 4 (1.5%)
Nausea 2 (0.7%) 3 (1.1%)
Fatigue 3 (1.2%) 0
Thirst 1 (0.4%) 3 (1.1%)
Headache 7 (2.5%) 5 (1.8%)
Sedation/somnolence 3 (1.1%) 1 (0.4%)
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